SCHEMBL2048840

SCHEMBL2048840

CCN(C)CCCOc1cc2ncnc(Nc3cnn(CC(=O)Nc4cccc(F)c4)c3)c2cc1OC

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT4 P35916 4/20 0.82
PDGFRB P09619 3/20 0.82
FLT3 P36888 3/20 0.82
AURKA O14965 11/20 0.65
CSF1R P07333 1/20 0.64
AURKB Q96GD4 4/20 0.58
EGFR P00533 4/20 0.55
KDR P35968 3/20 0.55
LCK P06239 1/20 0.52
IGF1R P08069 1/20 0.52
FGFR1 P11362 1/20 0.52
SRC P12931 1/20 0.52
FGFR2 P21802 1/20 0.52
FGFR4 P22455 1/20 0.52
FGFR3 P22607 1/20 0.52
CDK2 P24941 1/20 0.52
CSK P41240 1/20 0.52
JAK3 P52333 1/20 0.52
PTK2 Q05397 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2047693 0.96 FLT4 (0.82) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2053594 0.95 FLT4 (0.77) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2049955 0.94 FLT4 (0.81) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2051279 0.94 FLT4 (0.81) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL3429103 0.94 FLT4 (0.83) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2048586 0.92 FLT4 (0.78) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2048681 0.92 FLT4 (0.81) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2051635 0.92 FLT4 (0.77) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2052538 0.92 FLT4 (0.77) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2053127 0.92 FLT4 (0.77) FLT4PDGFRBFLT3AURKACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4709139-B2 2011-06-22 JP claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US claimed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP claimed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US claimed
JP-2006523660-A 2006-10-19 JP claimed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 FLT4 2898/4885PDGFRB 1544/4885FLT3 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.